Jonathan Zalevsky
Chief R&D Officer · 6 filings · Latest: Jul 24, 2026
NEKTAR THERAPEUTICS
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
NKTR | Jonathan Zalevsky | Chief R&D Officer | Jun 30, 2026 | Sale | $70.00 | 5,681 | $397.7K | 9,756 | |
NKTR | JONATHAN ZALEVSKY | — | Jun 30, 2026 | Proposed Sale | $65.39 | 5,681 | $371.5K | — | |
NKTR | Jonathan Zalevsky | Chief R&D Officer | Jun 15, 2026 | Sale | $60.71 | 5,538 | $336.2K | 15,437 | |
NKTR | JONATHAN ZALEVSKY | — | Jun 15, 2026 | Proposed Sale | $59.38 | 5,538 | $328.8K | — | |
NKTR | Jonathan Zalevsky | Chief R&D Officer | May 19, 2026 | Sale | $65.51 | 199 | $13.0K | 20,975 | |
NKTR | Zalevsky Jonathan | — | May 19, 2026 | Proposed Sale | $65.51 | 199 | $13.0K | — | |
NKTR | Jonathan Zalevsky | Chief R&D Officer | Feb 18, 2026 | Sale | $73.00 | 180 | $13.1K | 21,174 | |
NKTR | Zalevsky Jonathan | — | Feb 18, 2026 | Proposed Sale | $73.00 | 180 | $13.1K | — | |
NKTR | Jonathan Zalevsky | Chief R&D Officer | Jan 20, 2026 | Sale | $35.67 | 3,867 | $137.9K | 21,354 | |
NKTR | Zalevsky Jonathan | — | Jan 20, 2026 | Proposed Sale | $35.67 | 3,867 | $137.9K | — | |
NKTR | Zalevsky Jonathan | — | Nov 25, 2025 | Proposed Sale | $58.82 | 1,157 | $68.1K | — | |
NKTR | Zalevsky Jonathan | — | Sep 4, 2025 | Proposed Sale | $33.52 | 1,721 | $57.7K | — | |
NKTR | Zalevsky Jonathan | — | Sep 2, 2025 | Proposed Sale | $30.10 | 485 | $14.6K | — | |
NKTR | Zalevsky Jonathan | — | Aug 19, 2025 | Proposed Sale | $26.59 | 725 | $19.3K | — | |
NKTR | Zalevsky Jonathan | — | May 19, 2025 | Proposed Sale | $0.6713 | 10,712 | $7.2K | — | |
NKTR | Zalevsky Jonathan | — | Feb 19, 2025 | Proposed Sale | $1.01 | 10,300 | $10.4K | — | |
NKTR | Zalevsky Jonathan | — | Dec 19, 2024 | Proposed Sale | $0.9403 | 51,115 | $48.1K | — | |
NKTR | Zalevsky Jonathan | — | Nov 19, 2024 | Proposed Sale | $1.01 | 7,785 | $7.9K | — |